undamentalytics Newsletter
Sign in

Veracyte, Inc. income statement

In fiscal 2025, Veracyte, Inc. reported revenue of $517m, up 16.0% on the year before, operating income of $57.8m (a 11.2% margin) and net income of $66.4m, or $0.82 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue312223850657292120117220297361446517562
Cost of revenue3813172125283336———————
Gross profit−049222840445984——176230298363403
Research and development77810131514151517304157697193
Selling and marketing381322252832415452809810195100106
General and administrative581219232423242937101738611111196
Operating income−15−19−23−29−33−29−27−22−15−35−82−41−861658106
Interest expense——00035210——————
Income before tax−14−19−26−29−34−31−31−23−13−35−82−36−772668116
Income tax——00000000−60−2222
Net income−14−19−26−29−34−31−31−23−13−35−76−37−742466114
Diluted EPS−$4.98−$5.74−$1.23−$1.36−$1.30−$1.09−$0.91−$0.62−$0.27−$0.66−$1.11−$0.51−$1.02$0.31$0.82$1.40
Diluted shares (average)3m3m21m22m26m29m34m37m46m53m68m72m73m78m81m82m
EBITDA−15−18−22−28−31−25−23−18−11−27−62−15−594079127

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AZTA vs VCYTTXG vs VCYTTWST vs VCYT

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Veracyte, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Veracyte, Inc.